Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3614973 | 1.00 | KDM4E (0.53) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL1580113 | 0.79 | KDM4E (0.54) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL1580114 | 0.79 | KDM4E (0.54) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL9757025 | 0.78 | KDM4E (0.53) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL22165730 | 0.78 | GRM4 (0.58) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL9756857 | 0.78 | KDM4E (0.53) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL22776708 | 0.78 | KDM4E (0.53) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL22776706 | 0.78 | KDM4E (0.53) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL5756784 | 0.78 | KDM4E (0.58) | KDM4ELMNAHDAC3HDAC4HDAC1 | |
| SCHEMBL5756780 | 0.78 | KDM4E (0.58) | KDM4ELMNAHDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807263-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | Amphista Therapeutics Ltd (GB) | 2021-04-21 | — | — | EP | disclosed |
| WO-2019238816-A1 | BIFUNCTIONAL MOLECULES FOR TARGETING UCHL5 | UNIVERSITY OF DUNDEE (GB) | 2019-12-19 | — | — | WO | disclosed |
| US-10005741-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-05-24 | — | — | US | disclosed |
| US-9908856-B2 | Therapeutic compounds | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2018-03-06 | — | — | US | disclosed |
| US-9624194-B2 | Heteroaryl compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-01-12 | — | — | US | disclosed |
| US-9376420-B2 | 4,5-dihydro-1H-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same | YUHAN CORPORATION (KR) | 2016-06-28 | — | — | US | disclosed |
| US-20160052911-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2016-02-25 | — | — | US | disclosed |
| US-9181185-B2 | Heteroaryl compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150291563-A1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVE OR SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YUHAN CORPORATION (KR) | 2015-10-15 | — | — | US | disclosed |
| WO-2015130973-A1 | THERAPEUTIC COMPOUNDS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20140288092-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-25 | — | — | US | disclosed |
| WO-2013064883-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-8304438-B2 | Heteroarylacrylamides and their use as pharmaceuticals | SANOFI (FR) | 2012-11-06 | — | — | US | disclosed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2099753-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-09-16 | — | — | EP | disclosed |
| EP-1939180-A1 | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074413-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288092-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN1B, SCN2B, SCN1A | KDM4E 2357/4885LMNA 1412/4885HDAC3 792/4885 |
| US-20160052911-A1 | HETEROARYL COMPOUNDS AS SODIUM CHANNEL BLOCKERS | SCN1B, SCN2B, SCN1A | KDM4E 2357/4885LMNA 1412/4885HDAC3 792/4885 |
| US-20150291563-A1 | 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVE OR SALTS THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | NR1H3, NR1H2, NR1H4 | KDM4E 2018/4885LMNA 4200/4885HDAC3 86/4885 |
| US-20170008859-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | KDM4E 3451/4885LMNA 4506/4885HDAC3 1885/4885 |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | NOS3, PTGIS, NOS1 | KDM4E 1785/4885LMNA 2492/4885HDAC3 2103/4885 |
| US-20180141921-A1 | THERAPEUTIC COMPOUNDS | IAPP, PARK7, NLN | KDM4E 3451/4885LMNA 4506/4885HDAC3 1885/4885 |
| US-10005741-B2 | Therapeutic compounds | IAPP, PARK7, NLN | KDM4E 3451/4885LMNA 4506/4885HDAC3 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.